With Dueling Papers Comes A Spirited Debate About Stapled Peptides
This article was originally published in Start Up
The new, promising class of drugs is rolling toward the clinic, but a respected research group recently thrust a stick in the spokes and prompted a call for wider access to the technology.
You may also be interested in...
At Elsevier Business Intelligence's recent Therapeutic Area Partnerships conference, a roundtable of senior pharmaceutical executives and entrepreneurs weighed in on industry’s current funding challenges, how dealmaking defines a biotech’s ambitions and strategy, and pharma’s appetite for early-stage innovation.
As emerging technologies begin to overcome peptide therapeutics’ pharmacologic limitations, their compelling potential grows clearer and their deal value has grown. Most if not all of Big Pharma and Big Biotech now have rebuilt their internal peptide drug development programs and show interest in start-ups with peptide pipelines and platforms.
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.